HEMGENIX OPTIONS

Number of eligible patients: CDEC mentioned the uncertainty in the amount of sufferers with moderately significant to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical professionals consulted by CADTH indicated that some people who will be categorised as getting mild or average disorder could possibly have a significant